Stereotactic Radiotherapy for Elderly Patients with Pancreatic Cancer
Author Information
Author(s): Fiore Michele, Petrianni Gian Marco, D’Ercole Gabriele, Onorati Elena, Trecca Pasquale, Alaimo Rita, Carlotti Daniele, Ippolito Edy, D’Angelillo Rolando Maria, Ramella Sara
Primary Institution: Università Campus Bio-Medico di Roma
Hypothesis
This study aims to evaluate the efficacy and safety of SBRT in elderly pancreatic cancer patients.
Conclusion
SBRT appears to be an effective and safe option for elderly pancreatic cancer patients, achieving high local control with minimal toxicity.
Supporting Evidence
- The 1-year, 2-year and 3-year LPFS rates were 88%, 73% and 54%, respectively.
- Median PFS, MFS and OS were 29.6 months, 32.6 months, and 24.1 months, respectively.
- SBRT was well tolerated with acute and late toxicity rates of 6% and 9%, respectively.
- Patients who received chemotherapy had a significantly longer median OS compared to those who did not.
Takeaway
Doctors used a special type of radiation treatment called SBRT to help older people with pancreatic cancer, and it worked well with few side effects.
Methodology
Patients received SBRT using Volumetric Modulated Arc Therapy in schedules of five dose fractions tailored to the tolerance of adjacent tissues.
Potential Biases
The retrospective nature of the study and the variety of chemotherapy regimens used may introduce selection bias.
Limitations
The sample size is relatively small and the follow-up period is limited, which may limit the evaluation of long-term outcomes.
Participant Demographics
The mean age of participants was 77 years, with 11 males and 22 females.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 23.6–43
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website